Effect of platelet-activating factor and its specific receptor antagonist on glomerular permeability to proteins in isolated perfused rat kidney.
Platelet-activating factor (PAF) is a lipid mediator of inflammation believed to play a role in glomerulonephritis by favoring immune complex formation and modulating the subsequent inflammatory reaction. Some evidence indicates that PAF may also be one of the mediators of proteinuria. Previous work suggested that PAF can increase glomerular permeability to proteins, activating platelets and inflammatory cells to release cationic proteins. In the present study, we addressed the possibility that PAF might directly increase glomerular permeability to proteins independently of platelets and inflammatory cells. We used a preparation of isolated rat kidney perfused with an artificial cell-free medium. After stabilization and two 10-minute control clearance periods, kidneys perfused in a closed circuit were exposed to PAF (2 nM or 10 nM final concentration) or 2-lyso-PAF (10 nM final concentration) or vehicle for 40 minutes. Glomerular filtration rate, measured as creatinine clearance, and renal vascular resistance did not significantly change when either PAF (2 nM or 10 nM) or 2-lyso-PAF, or vehicle were added to the perfusion fluid. Unlike vehicle or 2-lyso-PAF, addition of PAF at the final concentration of 2 and 10 nM to the perfusate produced a dose-dependent progressive increase in urinary protein excretion. PAF-induced proteinuria was prevented by L-652,731, a specific PAF receptor antagonist, suggesting that PAF's effect on glomerular permeability to proteins is likely to be related to its biologic activity. Several pharmacologic manipulations addressed to the potential mediators of PAF effect on glomerular permeability to proteins would exclude that the effect of PAF on isolated perfused kidney is mediated by cyclooxygenase or lipoxygenase products, or is the result of oxygen-free radical generation. The possibility that PAF enhances glomerular permeability to proteins by changing the glomerular barrier electrostatic properties was explored using polyethylene-imine. Electron microscopy examination revealed no difference in the distribution of electron-dense deposits along the glomerular basement membrane in kidneys exposed to 10 nM PAF or vehicle.
D015772:4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D001485:Basement Membrane / Q000648:ultrastructure; D002463:Cell Membrane Permeability; D016861:Cyclooxygenase Inhibitors; D005663:Furans / Q000494:pharmacology*; D005919:Glomerular Filtration Rate; D007213:Indomethacin / Q000494:pharmacology; D007678:Kidney Glomerulus / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology / Q000648:ultrastructure; D016859:Lipoxygenase Inhibitors; D008297:Male; D008854:Microscopy, Electron; D010477:Perfusion; D010640:Phenothiazines / Q000494:pharmacology*; D010972:Platelet Activating Factor / Q000378:metabolism / Q000494:pharmacology*; D011506:Proteins / Q000378:metabolism*; D011507:Proteinuria / Q000209:etiology*; D011720:Pyrazoles / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D014655:Vascular Resistance
D000975:Antioxidants; D016861:Cyclooxygenase Inhibitors; D005663:Furans; D016859:Lipoxygenase Inhibitors; D010640:Phenothiazines; D010972:Platelet Activating Factor; D011506:Proteins; D011720:Pyrazoles; D015772:4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine; C053726:4-bromo-2,7-dimethoxy-3H-phenothiazin-3-one; C047504:2,5-bis(3,4,5-trimethoxyphenyl)tetrahydrofuran; D007213:Indomethacin